A clone of the interleukin 2-producing Jurkat leukemia cell line termed JA3 (surface phenotype, T31, Ti+, T44+, T11+, T40+) has been used to induce and select cell variants lacking surface molecules involved in T-cell activation.
T44+, T11+, T40+) has been used to induce and select cell variants lacking surface molecules involved in T-cell activation. Following 200 rad of V-radiation (1 rad = 0.01 Gy), cells were treated with monoclonal antibodies (mAbs) directed to T3, Ti, T44, or T11 antigen and complement. After growth of the residual cells in culture, "negative" cells were cloned under limiting conditions. Depending on the specificity of the mAb used for the immunoselection, three groups of variants were obtained. (i) The use of mAbs directed to T3 or Ti resulted in cell variants that expressed the T3-Ti-T44' Leul+ T11' T40' 4F2' HLA class I+ surface phenotype. (ii) Immunoselection with anti-T44 mAb resulted in 2 variants that shared the T3-Ti-T44-Leul-T11' T40' 4F2+ HLA class I+ phenotype. (iii) Cell treatment with anti-T11 mAb resulted in 15 variants characterized by the lack of T11 antigen expression and of all the other T-cell-specific surface antigens. Therefore, it appears that the different sets of JA3 cell variants, like T cells at discrete stages of intrathymic differentiation, may follow a coordinated expression of surface differentiation antigens. Analysis of the functional responsiveness of the three distinct groups of JA3 cell variants to different stimuli showed that all produced interleukin 2 in response to A23187 calcium ionophore plus phorbol 12-myristate 13-acetate. The first group of variants (T3-Ti-) did not respond to stimulation with anti-T3, anti-Ti, or anti-T44 mAbs. Eight of 9 did not respond to phytohemagglutinin either; however, all responded to appropriate stimulatory combinations of anti-T11 mAbs (and to calcium ionophore). The second group of variants (T3-, Ti-, T44-, T11+), similar to the first group, did not respond to anti-T3, anti-Ti, anti-T44 mAbs, and phytohemagglutinin, but they were fully responsive to anti-T11 mAb. The last group of variants (lacking all the T-cell-specific surface antigens) only responded to calcium ionophore A23187.
It has recently been shown that activation of human T lymphocytes can occur via one of three distinct pathways. Thus, triggering of the antigen receptor complex (formed by the heterodimeric structures carrying clonotypic determinants, Ti, and by the nonpolymorphic T3 molecules) can be achieved through the binding of nominal antigens in the context of major histocompatibility complex-encoded products (1) . In addition, activation via the antigen receptor complex can be induced by monoclonal antibodies (mAbs) directed to T3 or Ti molecules (2) . A second pathway through which human T cells can be activated is represented by the 50-kDa T11 sheep erythrocyte binding protein. Although the precise identity of the natural ligand(s) for T11 molecules is still under investigation (3, 4) , it has been shown that the combined use ofmAbs directed to distinct epitopes ofthe T11 molecule leads to T-cell activation (5) . The third pathway of T-cell activation is initiated by the T44 cell-surface glycoprotein after interaction with specific mAbs (6, 7) .
Recent studies have been aimed at understanding the functional relationship existing among the three distinct pathways of T-cell activation. A major finding was that mAb-induced modulation of the T3-Ti antigen receptor complex led to unresponsiveness not only to anti-T3 or anti-Ti mAbs but also to anti-T11 (5) or anti-T44 mAbs (6) . These results suggested that both T11 and T44 pathways of activation may be "regulated" by surface expression of the T-cell receptor complex.
A useful approach to better define the functional and physical relationship among different surface molecules involved in human T-cell activation is represented by the study of "functional" T-cell lines and their variants. This approach has been recently applied by Weiss and Stobo (8) to the analysis of T3-Ti negative variants derived from the interleukin 2 (IL-2)-producing Jurkat leukemic T-cell line.
In the present study, we analyzed the functional capability of phenotypically distinct cell variants derived by immunoselection with mAb and complement from the IL-2-producing JA3 cell line (9) following low dosages of irradiation. JA3 cells do not express detectable T4 or T8 surface antigens and exhibit the T3' Ti+ T44' Leu-1+ T11' T40' (3A1) 4F2' HLA class I' surface phenotype.
Variants obtained by immunoselection with mAbs directed against T3 or Ti surface molecules were characterized by the simultaneous loss of both surface molecules. The second group was obtained by negative selection against the T44 surface antigen: the resulting T44-variants were also found to lack T3, Ti, and Leu-1 antigens. The third set of variants was obtained by immunoselection against surface T11 antigen: all the variants lacked all T-cell-specific markers but they still expressed 4F2 and HLA class I antigens. These data suggest the existence of a coordinated expression of surface T-cell antigens similar to that occurring at discrete stages of intrathymic differentiation (10) . Functional studies of the three distinct sets of variants indicated that the T44 pathway of activation is functionally dependent on the "classical" pathway initiated by the T3-Ti receptor complex. In contrast and in partial disagreement with previous conclusions based on different approaches, the T11 pathway can be triggered even in the absence of the T3-Ti surface molecules.
MATERIALS AND METHODS Cells. The IL-2-producing JA3 cell line was derived from Jurkat T-ALL as described (9) . The selection of the JA3 subclone was based on the high levels of IL-2 production and the expression of surface T3 antigen (6, 9) .
The CTLL-2 murine IL-2-dependent T-cell line was used as described in detail elsewhere (10) .
Derivation of JA3 Variants. Cell variants were obtained after y-irradiation of JA3 cells with 200-300 rad (1 rad = 0.01 Gy) using a cesium source. Cells were then cultured in the presence of peritoneal macrophages for 2-3 days before immunoselection with mAb and complement. To this end, 1.5 x 106 mutagenized JA3 cells were negatively selected with OKT3 (anti-T3) mAb (final dilution, 1:200) or JTi2 (anti-Ti) mAb (1:400 of the ascitic fluid), or 9.3 (anti-T44) mAb (final dilution, 1:100) or 9.6 (anti-T11) mAb (final dilution, 1:200) and rabbit complement preadsorbed with JA3 cells (final dilution, 1:4) . Cells were treated with complement for 90 min at 37°C, residual cells were pelleted, washed twice in RPMI 1640 medium, and then resuspended in 12 ml of culture medium. Such cell suspension was then subdivided in 1-ml aliquots and cultured in flat-bottomed wells in the presence of peritoneal adherent cells. Treatment with anti-T3, anti-Ti, and anti-T11 required only one-step selection to obtain negative variants, whereas to derive T44-variants, cells were treated twice with mAb and complement. Screening of T3-/Ti-, T44-, and T11-variants was performed by indirect immunofluorescence and fluorescence-activated cell sorting analysis (FACS II; Becton Dickinson) as described (6) . When necessary (as in the case of anti-T44-treated cells), negative cells were separated from the few positive cells by sorting.
Immunoprecipitation. JA3 cells and their variants were washed five times in phosphate-buffered saline (PBS) and resuspended at 2 x 106 cells per ml in methionine-free RPMI 1640 medium contarining 2.5% dialyzed fetal calf serum. Cells were incubated at 37°C for 4 hr in the presence of [35S]methionine (1 mCi per 100 ml; 1 Ci = 37 GBq). After incubation, cells were washed three times in PBS and resuspended in lysis buffer [10 mM Tris-buffered saline (pH 7.5) containing 1% Nonidet P-40, 1 mg of bovine serum albumin per ml, and 0.1 mM phenylmethylsulfonyl fluoride]. Cells were lysed for 20 min at 4°C. The supernatants were then immunoprecipitated as described (6) . The immunoprecipitate was eluted from protein A-Sepharose by boiling for 2 min in 5% sodium dodecyl sulfate (NaDodSO4) and analyzed on 11% discontinuous NaDodSO4/polyacrylamide gel (11) .
mAbs. The anti-T3 mAbs used in these studies were OKT3, which was used for the immunoselection of T3-negative variants (Ortho Diagnostics), Leu-4 (Becton Dickinson), which was used in immunoprecipitation studies, and JT3A, which was used in the functional assays and in indirect immunofluorescence analysis. The anti-T44 mAb (9.3) was a generous gift of J. Hansen (Fred Hutchinson Cancer Research, Seattle, WA). Anti-Leu-1 mAb was purchased from Becton Dickinson. Stimulatory anti-T11 mAbs (CD2-1, CD2-9, MAR 206) were derived as described (12, 13) , whereas the 9.6 mAb (also recognizing the T11 antigen) was purchased from New England Nuclear. The JTi2 mAb recognizing the T-cell receptor of JA3 cells has been described in detail elsewhere (9, 14) . The B9.12 (anti-HLA class I) mAb was obtained as described (15) . The 4F2 and 3A1 (anti-T40) mAbs were a generous gift of A. S. Fauci (National Institutes of Health, Bethesda, MD). An additional anti-T40 mAb (MAR 21) obtained in our laboratory was used for indirect immunofluorescence analysis.
IL-2 Production Assay. The assay used to determine the levels of IL-2 production by JA3 cells has been described in detail elsewhere (9) . Phorbol 12-myristate 13-acetate (PMA) was used at 10 ng/ml, phytohemagglutinin (PHA) was used at 1% (vol/vol), A23187 was used at 1 ,g/ml, JT3A (anti-T3) and JTi2 (anti-Ti) mAbs were used at a final dilution of 1:20 of the hybridoma supernatant, the anti-T11 mAbs were used at a final dilution of 1:400 of the ascitic fluid, the anti-T44 mAb was used at 1:300 of the ascitic fluid, and the Leu-1 was used at 1:200 of the stock solution.
RESULTS
Derivation of Cell Variants. Variants of JA3 cells lacking the expression of various T-cell antigens were derived as described (8) by mutagenesis of JA3 cells with y-radiation followed by negative immunoselection using mAbs specific for either T3, Ti, T44, or T11 molecules. After growth of the residual cells in multiple macrowell cultures, growing cultures were analyzed by fluorescence-activated cell sorting. In the case of anti-T3-, anti-Ti-, and anti-T11-treated cells, proliferating cultures were consistently represented by cells lacking the relevant antigens. Therefore, no further selection by cell sorting was necessary. In contrast, anti-T44-treated cells contained in some instances T44+ cells. In this case, T44-cells were further purified by cell sorting. After this further purification, the T44-variants maintained a stable phenotype. The experimental approach used does not allow a precise evaluation of the frequency with which the various variants arise. However, we could roughly estimate (based on the initial number of treated cells and on the number of selected variants) that the frequency was at least 1:2.5 x 105 for variants selected against T3 or Ti, 1:2 x 106 for variants selected against T11, and 1:1.5 x 106 for variants selected against T44. To ensure the clonality of the population analyzed, each of the negative variants was further cloned under limiting dilution conditions. Negative selection imposed by the use of either anti-T3 or anti-Ti mAbs and complement consistently resulted in cell variants that were negative for both T3 and Ti antigens, in agreement with a recent report by Weiss and Stobo (8) . Nine cloned cell variants were analyzed by indirect immunofluorescence for the expression of other surface antigens that are normally expressed by JA3 cells. In all instances, these variants exhibited the T3-Ti-T44+ Leu-1+ T11+ T40+ 4F2+ HLA class I' phenotype. One representative clone is shown in Fig.  1 and Table 1 . Negative selection utilizing anti-T44 mAb and complement resulted in two variants (P-Cl and P-F2) lacking the surface expression of T44 antigen. It is noteworthy that both variants that had been selected in two different experiments exhibited the T3-Ti-T44-Leu-1-T11+ T40+ 4F2+
HLA class I' surface phenotype ( Fig. 1 Appropriate Stimuli Can Induce IL-2 Production by All Variants. To evaluate whether the variants obtained by immunoselection had maintained the capability of producing IL-2 upon stimulation, the various types of variants were compared to JA3 for their ability to respond to the calcium ionophore A23187 in the presence of PMA. As shown in previous reports (6, 9) , addition of PMA is required for JA3 responses to PHA or to mAbs directed to T3, Ti, or T44 molecules. Similarly, the A23187 calcium ionophore elicits low IL-2 production by JA3 when used alone, whereas it induces maximal IL-2 production when combined with PMA. As shown in Table 2 , all the variants obtained by negative immunoselection were capable of producing IL-2 when stimulated with A23187 in the presence of PMA. Minor variations in the levels of IL-2 production were observed among the variants: -2-fold differences were observed between the amount of IL-2 produced by JO2 (T3-Ti-T44-Leu-1-T11-T40-4F2+, HLA class I') and by P-Cl (T3-Ti-T44-Leu-1-T11+ T40+) (90 and 185 units/ml, respectively). Table 3 , all the variants failed to respond to anti-T3 or anti-Ti mAbs. Moreover, 8 of 9 were also unresponsive to PHA. The AD2 variant, however, was still highly responsive to PHA. Since both T44 and T11 antigens were normally expressed in this set of variants, we next analyzed their ability to respond to anti-T44 mAbs. All the variants, including AD2, were unresponsive to anti-T44 mAb.
The same set of variants was then analyzed for the ability to respond to anti-T11 mAb stimulation. Induction of T-cell activation via T11 surface molecule requires appropriate combinations of mAbs directed against different epitopes of the molecule (5). We used two different combinations of anti-T11 mAbs that had previously been shown to induce optimal production of IL-2 from JA3 in the presence of PMA (13, 16) . As shown in Table 3 , all T3-Ti-T44+ Leu-1+ T11+ variants were responsive to anti-T11-mediated stimulation. Moreover, no differences could be detected between the response of AD2 and those of the other variants. These data indicate that (i) the pathway of T-cell activation initiated by T11 molecules is not dependent on the surface expression of the T3-Ti receptor complex; (ii) the T44-and the T11-dependent pathways of T-cell activation can function independently since lack of expression of the T3-Ti receptor complex renders cells unresponsive to anti-T44 but not to anti-T11 mAbs; and (iii) although T11 appears to be a PHA-binding protein (17) , there is no evidence in favor of a functional correlation between cell activation via T11 molecules and cell triggering by PHA. Indeed, all of the T3-Ti-T44+ Leu-1+ T11+ variants responded efficiently to anti-T11 mAbs, whereas only one (AD2) responded to PHA. Thus, the capacity of AD2 to respond to PHA appears not to be correlated with the expression or the function of T3, T44, or T11 antigen. Since it could not be excluded that AD2 expressed low amounts of T3 at the cell surface, we performed experiments of internal labeling (35S) followed by immunoprecipitation with anti-T3 mAb. As shown in Fig. 2 , no T3 antigen could be precipitated from the AD2 cell lysate. Similar results were obtained with six other T3-T44+ T11+ variants analyzed (not shown). However, from a single T3-T44+ T11+ cell variant (termed BC2), the anti-T3 immunoprecipitate contained a single band of -19 kDa, which corresponded to one of the two major chains ofthe T3 antigen immunoprecipitated from JA3. Note, however, that unlike AD2, the BC2 variant was unable to produce IL-2 in response to PHA. Functional Analysis of JA3 Variants Obtained by Negative Selection with Anti-T44 mAb and Complement. As shown above, cell variants obtained by immunoselection with anti-T44 mAb (P-Cl and P-F2) were characterized by the T3-Ti-T44-Leu-1-T11+ T40+ 4F2+ HLA class I' surface phenotype. Table 4 indicates that these variants were not responsive to stimulation with anti-T44, anti-T3, or anti-Ti mAbs and PHA, whereas responses to anti-T11 mAb stimulation were similar to those of JA3 parental cells. Therefore, cell triggering via the T11 molecules can occur in cell variants that lack T44 and Leu-1 surface antigens in addition to the T3-Ti receptor complex. It is also noteworthy that PHA was unable to stimulate this set of T11+ variants.
Functional Analysis ofJA3 Cell Variants Obtained by Negative Selection with Anti-Til mAbs and Complement. The last group of variants obtained by immunoselection with anti-T11 mAb was characterized by the T3-Ti-T44-Leu-1-T11-T40-4F2+ HLA class I' phenotype. Only one variant had minimal amounts ofthe T40 (3A1) antigen known to be expressed before T11 during T-cell ontogeny (18) . Although this finding may suggest that surface expression of T40 may be independent of that of T11, it should be stressed that 14 additional JA3 cell variants lacking T11 were also lacking T40 antigen.
All these T11-variants did not respond to anti-T11, anti-T44, anti-T3, anti-Ti mAbs or PHA, although they responded to A23187 (Table 4) . DISCUSSION In the present study, we selected T-cell variants lacking various surface molecules that are involved in different pathways of T-cell activation. Since these variants were derived from the IL-2-producing JA3 leukemic cell line and had maintained the ability to produce IL-2 in response to stimulation with the calcium ionophore A23187 and PMA, we could study their responsiveness to a variety of stimuli and thus analyze the relationship existing among different pathways of T-cell activation. It should be stressed that for mutagenesis and immunoselection we used the cloned JA3 cell population to obtain cell variants derived from a homogeneous population with well-defined phenotypic and functional characteristics.
We showed in previous reports that JA3 cells release IL-2 upon stimulation with PHA or mAbs directed to T3, Ti, T44, or T11 antigens (in the presence of PMA or adherent cells) (6, 9, 16) . Following mAb-induced modulation of the T3-Ti receptor complex, JA3 cells became refractory to stimulation with anti-T3 or anti-Ti mAbs (6) . In addition, although these cells fully expressed both T44 and Til surface antigens, they were also unresponsive to anti-T44 and anti-T11 mAbs or PHA (16) . Responses were restored after a time interval of 48-56 hr that coincided with the reexpression of T3-Ti surface molecules. Antibody-induced modulation of T44 or Til surface antigens, on the contrary, had no effect on the cell stimulation via the T3-Ti receptor complex (6, 16) . Moreover, modulation of T44 antigen did not interfere with the Til-dependent pathway of activation and, vice versa, modulation of T11 molecules did not inhibit the T-cell responses to anti-T44 mAb (16) .
The present data indicate that the JA3 T3-Ti antigen-loss variants, like JA3 cells modulated with anti-T3 or anti-Ti mAbs, were refractory to stimulation with anti-T44 mAb. However, these variants, unlike modulated cells, were fully responsive to appropriate stimulatory combinations of anti-T11 mAbs. These results suggest that the phenomenon of modulation of the T3-Ti antigen receptor complex may represented by an anti-T111 (CD2-9) and an anti-Tll2 (CD2-1) mAb.
The various mAbs were used under the same conditions described in Table 2 . ND, not done.
actually induce a reversible status of tolerance to any further T-cell stimulation. Conversely, the simple lack of expression of T3-Ti molecules, as it occurs in the T3-Ti negative variants, does not affect the pathway of activation initiated by T11 molecules (but leads to unresponsiveness to stimuli acting either on T3-Tj or T44 molecules). In this context, it is noteworthy that Fox et al. (19) reported that stage II thymocytes (surface phenotype, T3 Ti-T11+) express receptors for IL-2 after incubation with stimulatory combinations of anti-Til mAbs. In addition, Siliciano et al. (20) showed that T3-T11+ clones with natural killer (NK) cell-like activity can be induced to kill NK-resistant tumor target cells after stimulation with the same combinations of anti-T11 mAbs. Although the JA3 cell variants selected in the present study may be comparable to neither NK Another noticeable finding of the present study was that the various sets of variants obtained by immunoselection appeared to follow a coordinated sequential loss of expression of the various T-cell lineage-specific markers. Thus, immunoselection against T44 antigen resulted in variants characterized by the simultaneous loss of T3-Ti and Leu-1 antigen; moreover, all the T1 cell variants did not express T3, Ti, T44, and Leu-1. In several independent experiments, we failed to obtain T3-Ti positive variants by immunoselecting against T44 or Til; conversely, immunoselection against T3 or Ti did not lead to T44-or T11-cell variants. Therefore, the pattern of expression of the various T-cell-specific markers on the cell variants appears to be similar to that found on thymocytes at discrete stages of differentiation (22) , which express first the T40 and T11 antigens, then the T44 antigen, and finally the T3,-Ti antigen receptor complex. All the T11-yariants, while lacking T-lineage-specific antigens, still expressed other markers that are not restricted to T cells. It is also noteworthy that one T11-cell variant expressed low levels of T40 (3A1 antigen. This is not surprising since T40 already appears to be expressed on prothymocytes (17) . The genetic basis by which these variants are arising remains to be 'determined. Several possibilities may be conceived: in some cases (T3-Ti negative variants), the absence of either one of the distinct subunits that is involved in a functional T3-Ti receptor complex could be responsible for the lack of antigen expression (see Fig. 2, lane a) . If this is the case, mutation or deletion (less likely) of the genes encoding a given subunit could be the cause; alternatively, fast degradation of mRNA should be considered. In other cases (lack of expression of many gene products), after negative immunoselection for a single gene product (for example, T11-variants), it is difficult to envisage mutations or deletion of several structural genes; a possible explanation could be the absence (due to structural variation of a single gene) of a product that in itself is able to regulate the expression at the geqomic level of a family of functionally related genes by a mechanism in trans, such as a positive activator or a repressor (23) . If this holds true, then the coordinate lack of expression of several T-cell differentiation markers suggests the existence (as we have mentioned) of a developmentally regulated program of gene expression mimicking the physiological one taking place in the thymus. 
